CD274 and melanoma: There are several anti-PD-1/PD-L1 monoclonal antibodies including pembrolizumab (Keytruda®), nivolumab (Opdivo®), avelumab (Bavencio®), durvalumab (Imfinzi®), cemiplimab (Libtayo®), atezolizumab (Tecentriq®), cosibelimab and INBRX-105 in several stages of clinical trial in melanoma.